한글목차

난소암은 세계에서 가장 치사율이 높은 부인과암의 하나입니다. 희귀암임에도 불구하고 난소암은 블록버스터 시장이며, 2022년 판매고 33억 달러에서 2032년에는 41억 달러로, CAGR 2.0%로 확대할 것으로 예상되고 있습니다. 난소암 환자는 일반적으로 백금 기반 화학요법에 잘 반응하며, 첫 번째 치료에서 완전관해를 달성합니다. 그러나 잔존 병변이 있는 환자는 재발 위험이 높습니다. 또한 화학요법 내성의 빠른 출현이 관찰됩니다. 현재 백금제제 내성 환자를 위한 표준 치료는 표적치료제(베바시주맙) 또는 세포독성 약물(탁산, 젬시타빈, 페그화 리포좀 독소루비신, 토포테칸)과의 병용요법 또는 비백금제제 단독요법으로 순차적으로 치료하고 있습니다. 난소암은 환자의 전체 생존기간 연장을 위한 1차 치료 옵션의 개선과 백금 내성 환자를 위한 대안적 치료 옵션에 대한 미충족 수요가 존재합니다.

PARP 억제제는 높은 치료율을 자랑하는 유지요법의 1차 선택약물로 자리매김하고 있으며, 앞으로도 1차 선택약물로서 시장 점유율을 유지할 것으로 예상됩니다.

세계의 난소암 치료제 시장에 대해 조사했으며, 질환의 개요와 역학 동향, 치료법과 미충족 요구, 파이프라인 동향 등에 대해 정리하여 전해드립니다.

목차

제1장 서문

제2장 주요 요약

제3장 질환의 개요

제4장 역학

• 난소암으로 진단된 증례, 여성, 연령 18세 이상, 2022-2032년
• 연령별 난소암 진단 건수(여성, 2022년)
• 조직학적 서브타입별 상피성 종양 진단 증례수, 여성, 연령 18세 이상, 2022년
• FIGO 스테이지별 난소암 진단 증례수, 여성, 연령 18세 이상, 2022년
• 2022년, 5년간 진단 유병률, 여성, 연령 18세 이상
• 난소암 진단 사례 정보원과 조사 방법
• 정보원과 조사 방법
• 정보원과 조사 방법 - 난소암 진단 발생률
• 정보원과 조사 방법 - 5년간 진단된 난소암의 유병률
• 정보원과 조사 방법 - 조직학적 서브타입별 상피성 종양 진단 증례

제5장 현재의 치료 옵션

• 난소암 치료 알고리즘
• 치료 패러다임 - 제일 선택 요법
• 치료 패러다임 - 플래티넘 현황
• 현재의 치료 옵션
• VEGF 저해제(아바스틴)의 제품 개요
• PARP 저해제의 제품 개요(Lynparza, Rubraca, Zejula)
• 키나아제 저해제(Rozlytrek)의 제품 개요
• 항체약물접합체(Elahere)의 제품 개요

제6장 미충족 요구와 기회

제7장 연구개발 전략

• 난소암 임상시험 디자인의 동향
• 난소암 거래 동향

제8장 파이프라인 평가

제9장 시장 전망

• 시험 스폰서별 난소암 임상시험
• 난소암 시장 예측
• 시장 촉진요인과 억제요인

제10장 부록

제11장 문의

영문목차

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being a rare cancer, ovarian cancer is a blockbuster market and is expected to grow from sales of $3.3 billion in 2022 to $4.1 billion in 2032 at a compound annual growth rate (CAGR) of 2.0%. Ovarian cancer patients generally respond well to platinum-based chemotherapy and achieve complete remission in the initial setting. However, the risk of recurrence for patients with residual disease is high. Additionally, the rapid emergence of chemotherapy resistance is observed. Currently, the standard treatment for platinum-resistant patients is sequential non-platinum treatment with either monotherapy or combination treatment with targeted therapy (bevacizumab) or cytotoxic agents (taxanes, gemcitabine, pegylated liposomal doxorubicin, or topotecan).There are several unmet needs in Ovarian Cancer that call for improved front-line treatment options and alternative options for platinum-resistant patients for extending overall survival in patients.

Major drivers of growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:

• The sales of ImmunoGen's Elahere represent the most impactful driver of growth for the ovarian cancer market. Elahere is anticipated to launch in the 5EU and Japan during the forecast period.
• Combinations of PARP inhibitors, VEGF inhibitors, and ICIs are expected to launch in the 7MM during the forecast period.
• New drug launches for novel therapies will take considerable market share from generic chemotherapies.
• PARP inhibitors are established in the front-line maintenance setting with high treatment rates and are expected to retain their market share in the first-line setting.

chemotherapies.

Major barriers to growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:

• High costs and issues with reimbursement associated with both front-line treatments and prospective novel therapies may reduce uptake and off-label usage.
• Voluntary withdrawals and generic erosion upon the patent expiries of the PARP inhibitors will temper sales growth during the forecast period in the ovarian cancer market.

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer.

These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData's World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being a rare cancer, ovarian cancer is a blockbuster market and is expected to grow from sales of $3.3 billion in 2022 to $4.1 billion in 2032 at a compound annual growth rate (CAGR) of 2.0%.

Key Highlights

• Report deliverables include a Pdf report and Excel-based forecast model
• Forecasts includes the 7MM
• Forecasts covers from 2022-2032
• GlobalData valued the Ovarian Cancer market in the 7MM at $3.3 billion and expects the market to increase to $4.1 billion by 2032
• ImmunoGen, AstraZeneca, Merck, and GSK are expected to take market-leading position in 2032
• A high level of unmet need will remain for most Ovarian Cancer patient populations during the forecast period
• The Ovarian Cancer late-stage R&D pipeline is widely varied with several novel therapeutic classes

Scope

Overview of Ovarian Cancer, including epidemiology, symptoms, diagnosis, and disease management.

Annualized Ovarian Cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Ovarian Cancer therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Ovarian Cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.

Analysis of the current and future market competition in the global Ovarian Cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Ovarian Cancer therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Ovarian Cancer therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Table of Contents

Table of Contents

1. Preface

• 1.1. Contents
• 1.2. Related Reports
• 1.3. Abbreviations

2. Executive Summary

3. Disease Overview

• 3.1. Overview of Ovarian Cancer
• 3.2. Ovarian Cancer Strengths, Weaknesses, Opportunities, and Threats Analysis
• 3.3. Classification of Ovarian Cancer

4. Epidemiology

• 4.1. Diagnosed Incident Cases of Ovarian Cancer, Women, Ages >=18 Years, 2022-32
• 4.2. Age-Specific Diagnosed Incident Cases of Ovarian Cancer, Women, 2022
• 4.3. Diagnosed Incident Cases of Epithelial Tumors by Histological Subtype, Women, Ages >=18 Years, 2022
• 4.4. Diagnosed Incident Cases of Ovarian Cancer by FIGO Stage, Women, Ages >=18 Years, 2022
• 4.5. Five-Year Diagnosed Prevalent Cases, Women, Ages >=18 Years, 2022
• 4.6. Sources and Methodology for Diagnosed Incident Cases of Ovarian Cancer
• 4.7. Sources and Methodology
• 4.8. Sources and Methodology - Diagnosed Incidence of Ovarian Cancer
• 4.9. Sources and Methodology - Five-Year Diagnosed Prevalent Cases of Ovarian Cancer
• 4.10. Sources and Methodology - Diagnosed Incident Cases of Epithelial Tumors by Histological Subtype

5. Current Treatment Options

• 5.1. Ovarian Cancer Treatment Algorithm
• 5.2. Treatment Paradigm - First-Line Therapy
• 5.3. Treatment Paradigm - Platinum-Status
• 5.4. Current Treatment Options
• 5.5. Product Profile of VEGF Inhibitor (Avastin)
• 5.6. Product Profiles of PARP Inhibitors (Lynparza, Rubraca, Zejula)
• 5.7. Product Profile of Kinase Inhibitor (Rozlytrek)
• 5.8. Product Profile of Antibody-Drug Conjugate (Elahere)

6. Unmet Needs and Opportunities

7. R&D Strategies

• 7.1. Trends in Ovarian Cancer Clinical Trial Design
• 7.2. Trends in Ovarian Cancer Deal-Making

8. Pipeline Assessment

• 8.1. Ovarian Cancer Pipeline Overview
• 8.2. Late-Stage Pipeline Agents for Ovarian Cancer
• 8.3. Product Profile of Verastem Oncology's avutometinib + defactinib
• 8.4. Product Profile of Zentalis Pharmaceuticals's azenosertib
• 8.5. Product Profile of Novartis's Femara (letrozole)
• 8.6. Product Profile of Alkermes's nemvaleukin
• 8.7. Product Profile of Corcept Therapeutics's relacorilant
• 8.8. Product Profile of Genelux's Olvi-vec (olvimulogene nanivacirepvec)
• 8.9. Product Profile of AstraZeneca's cediranib maleate
• 8.10. Product Profile of Advenchen Laboratories's catequentinib
• 8.11. Product Profile of AstraZeneca's Imfinzi (durvalumab)
• 8.12. Product Profile of Merck & Co's Keytruda (pembrolizumab)
• 8.13. Product Profile of Roche's Tecentriq (atezolizumab)
• 8.14. Product Profile of GSK's Jemperli (dostarlimab)
• 8.15. Product Profile of Bristol Myers Squibb / Ono Pharmaceuticals's Opdivo (nivolumab)
• 8.16. Product Profile of OncoQuest's oregovomab
• 8.17. Product Profile of Eisai / Bristol Myers Squibb's farletuzumab ecteribulin
• 8.18. Product Profile of Mersana Therapeutics's upifitamab rilsodotin
• 8.19. Product Profile of Sutro Biopharma's luveltamab tazevibulin

9. Market Outlook

• 9.1. Ovarian Cancer Clinical Trials by Trial Sponsors
• 9.2. Ovarian Cancer Market Forecast
• 9.3. Market Drivers and Barriers

10. Appendix

• 10.1. Primary Research - KOL Information
• 10.2. About the Authors

11. Contact Us